Stockreport

Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Zenas BioPharma, Inc.  (ZBIO) 
PDF -Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and suppor [Read more]